{"id":995023,"date":"2026-08-13T12:49:35","date_gmt":"2026-08-13T16:49:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/podd-deadline-suewallst-reminds-insulet-corporation-investors-of-upcoming-securities-class-action-deadline\/"},"modified":"2026-08-13T12:49:35","modified_gmt":"2026-08-13T16:49:35","slug":"podd-deadline-suewallst-reminds-insulet-corporation-investors-of-upcoming-securities-class-action-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/podd-deadline-suewallst-reminds-insulet-corporation-investors-of-upcoming-securities-class-action-deadline\/","title":{"rendered":"PODD DEADLINE: SueWallSt Reminds Insulet Corporation Investors of Upcoming Securities Class Action Deadline"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Alert: Claims Focus on Alleged<\/span> Defective Cannula Manufacturing That Caused Insulin Under-Delivery in Millions of Omnipod Devices<\/i>\n <\/p>\n

\n NEW YORK<\/span>, Aug. 13, 2026<\/span> \/PRNewswire\/ — SueWallSt reminds purchasers of Insulet Corporation (NASDAQ: PODD) securities of a pending securities class action.<\/p>\n

\n

\n \"SueWallSt.com\"\n <\/p>\n<\/p><\/div>\n

THE CASE: A class action seeks to recover damages for investors who purchased Insulet securities between February 21, 2025 and May 26, 2026.<\/p>\n

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you could be eligible to recover<\/a> or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/a>\u00a0or (888) SueWallSt.<\/p>\n

Insulet’s stock declined from approximately $236 to $146.01 per share across two corrective disclosures revealing systemic cannula defects, with approximately 7 million Pods affected by the May 2026 Medical Device Correction alone. Investors have until August 31, 2026 to seek lead plaintiff status.<\/p>\n

\n How a Cannula Tear Disrupts Insulin Delivery<\/b>\n <\/p>\n

An insulin pump company cannot fulfill its core promise to patients and investors if the device fails to deliver insulin as intended. The Omnipod system relies on a small flexible tube, called a cannula, to infuse insulin subcutaneously. The complaint alleges<\/span> that when that cannula has a tear, insulin may leak inside or outside the Pod rather than entering the patient’s body, resulting in under-delivery of a critical medication.<\/p>\n

The filing states that this defect was not limited to a single product generation. The May 2026 MDC affected Omnipod 5, Omnipod Dash, and Omnipod Eros Pods, all traced to cannula handling at Insulet’s Acton, Massachusetts facility.<\/p>\n

\n
\n Alleged<\/span> Cannula Defect Impact by the Numbers<\/b>\n <\/p>\n

As set forth in the complaint, the operational scope of the manufacturing failure was significant:<\/p>\n